Industry Satellite Symposia
Switch To Module
ESMO Congress 2021 - Conference Calendar
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Digital Evaluations
Everything
Everything
Session Title
Session Number
Presentation Title
Presentation Number
Author
Presenter
Chair
Filter By
Day
Select All
Deselect All
Fri, 17.09.2021
12
Sat, 18.09.2021
11
Sun, 19.09.2021
12
Mon, 20.09.2021
11
Tue, 21.09.2021
11
Room
Select All
Deselect All
Channel 3
14
Channel 4
15
Channel 5
13
Channel 6
15
Session Type
Select All
Deselect All
Industry Satellite Symposium
57
Presentation Type
Select All
Deselect All
Invited Speaker
57
Presentation Topic
Select All
Deselect All
General interest
57
Cancel
Clear
Search
Advanced Search
Sign in
Scheduled sessions
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Final Programme PDF
Browsing Over 57 Sessions
Sort By
Session Number
Upcoming First
Relevance
Session Number
Session Datetime
Pfizer Oncology - Complex Management of Relapsed and Refractory Multiple Myeloma (RRMM) and Evaluation of Unmet Needs
(ID 117)
Time
10:30 - 12:00
Mirati Therapeutics, Inc. - Rapid Progress During a Pandemic: Emerging Therapeutic Options for NSCLC
(ID 152)
Time
10:30 - 12:00
Novartis - Navigating the Current Treatment Landscape in Esophageal Cancer with an Eye Toward the Future
(ID 112)
Time
08:45 - 10:15
Bristol Myers Squibb - Shaping Tomorrow Today: What Does the Future Hold for Melanoma?
(ID 146)
Time
08:45 - 10:05
Medscape - A Stepwise Approach To Managing HR+/HER2- Early Breast Cancer: From Risk Assessment To Risk Management
(ID 107)
Time
18:45 - 20:15
Advanced Accelerator Applications, a Novartis Company - Actionable Targets in Advanced Prostate Cancer: The Potential of Molecular Profiling and Radioligand Therapy
(ID 141)
Time
10:30 - 12:00
Myriad Genetics - Developments in precision medicine for breast and ovarian cancers
(ID 136)
Time
08:45 - 10:15
ITM Isotopen Technologien München AG - A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy
(ID 102)
Time
10:30 - 12:00
GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
(ID 130)
Time
18:45 - 20:15
AstraZeneca - Redefining long-term outcomes in newly diagnosed advanced ovarian cancer: Expert perspectives on integrating personalized medicine
(ID 125)
Time
08:45 - 10:15
Janssen - Expanding horizons for the targeted management of EGFR-Positive NSCLC
(ID 119)
Time
18:45 - 20:15
Servier - Extend the continuum of care and improve patient outcomes in mGC and mCRC
(ID 154)
Time
17:35 - 19:05